Search results for "DRUG RESISTANCE"

showing 10 items of 953 documents

Role of AxyZ Transcriptional Regulator in Overproduction of AxyXY-OprZ Multidrug Efflux System in Achromobacter Species Mutants Selected by Tobramycin

2017

ABSTRACT AxyXY-OprZ is an RND-type efflux system that confers innate aminoglycoside resistance to Achromobacter spp. We investigated here a putative TetR family transcriptional regulator encoded by the axyZ gene located upstream of axyXY-oprZ . An in-frame axyZ gene deletion assay led to increased MICs of antibiotic substrates of the efflux system, including aminoglycosides, cefepime, fluoroquinolones, tetracyclines, and erythromycin, indicating that the product of axyZ negatively regulates expression of axyXY-oprZ . Moreover, we identified an amino acid substitution at position 29 of AxyZ (V29G) in a clinical Achromobacter strain that occurred during the course of chronic respiratory tract…

0301 basic medicineAchromobacterCefepime030106 microbiologyPopulationAchromobacterMicrobial Sensitivity TestsBiologymedicine.disease_causeMicrobiology03 medical and health scienceschemistry.chemical_compoundAntibiotic resistanceBacterial ProteinsMechanisms of ResistanceDrug Resistance Multiple BacterialTobramycinmedicineHumansPharmacology (medical)TetRAmino Acid Sequence[SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry Molecular Biology/Biochemistry [q-bio.BM]educationComputingMilieux_MISCELLANEOUSPharmacologyeducation.field_of_studyPseudomonas aeruginosaMembrane Transport Proteins[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologyGene Expression Regulation Bacterialbiology.organism_classification[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyAnti-Bacterial Agents3. Good healthInfectious DiseasesAmino Acid SubstitutionchemistryPseudomonas aeruginosaTobramycinTrans-ActivatorsEffluxGene DeletionBacterial Outer Membrane Proteinsmedicine.drugAntimicrobial Agents and Chemotherapy
researchProduct

Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infecti…

2018

ESGAP, ESGBIS, ESGIE and the CRGNB treatment survey study group.

0301 basic medicineAcinetobacter baumanniiCarbapenemAntibioticsDrug ResistanceDrug resistanceTigecyclineAcinetobacter baumannii; Carbapenem; Carbapenem-resistant Gram-negative bacilli; Combination therapy; Enterobacteriaceae; Polymyxin; Pseudomonas aeruginosa; SurveyPolymyxin0302 clinical medicineSurveys and Questionnairespolycyclic compounds030212 general & internal medicineAcinetobacter baumannii; Carbapenem; Carbapenem-resistant Gram-negative bacilli; Combination therapy; Enterobacteriaceae; Polymyxin; Pseudomonas aeruginosa; Survey; Anti-Bacterial Agents; Carbapenems; Cross Infection; Cross-Sectional Studies; Drug Resistance Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals; Humans; Microbial Sensitivity Tests; Surveys and QuestionnairesSurveyCarbapenemAcinetobacter baumannii; Carbapenem; Carbapenem-resistant Gram-negative bacilli; Combination therapy; Enterobacteriaceae; Polymyxin; Pseudomonas aeruginosa; Survey; Anti-Bacterial Agents; Carbapenems; Cross Infection; Cross-Sectional Studies; Drug Resistance Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals; Humans; Microbial Sensitivity Tests; Surveys and Questionnaires; Microbiology (medical); Infectious DiseasesCross InfectionbiologyMicrobial Sensitivity TestCarbapenem-resistant Gram-negative bacilliBacterialantibiotic management carbapenem-resistant Gram-negative bacteriaGeneral MedicineHospitals3. Good healthAcinetobacter baumanniiAnti-Bacterial AgentsInfectious DiseasesPseudomonas aeruginosamedicine.drugHumanMicrobiology (medical)medicine.medical_specialtymedicine.drug_class030106 microbiologyMicrobial Sensitivity TestsFosfomycincarbapenem-resistant Gram-negative bacteria03 medical and health sciencesHospitalEnterobacteriaceaeInternal medicineAnti-Bacterial AgentDrug Resistance BacterialGram-Negative BacteriamedicineGram-Negative Bacterial InfectionHumansCombination therapyCross-Sectional Studiebusiness.industrybiochemical phenomena metabolism and nutritionbiology.organism_classificationbacterial infections and mycosesCross-Sectional StudiesCarbapenemsInfectious disease (medical specialty)Carbapenem-resistant gram-negative bacilli[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieantibiotic managementbusinessGram-Negative Bacterial InfectionsRifampicin
researchProduct

Multifactorial Modes of Action of Arsenic Trioxide in Cancer Cells as Analyzed by Classical and Network Pharmacology

2018

Arsenic trioxide is a traditional remedy in Chinese Medicine since ages. Nowadays, it is clinically used to treat acute promyelocytic leukemia (APL) by targeting PML/RARA. However, the drug’s activity is broader and the mechanisms of action in other tumor types remain unclear. In this study, we investigated molecular modes of action by classical and network pharmacological approaches. CEM/ADR5000 resistance leukemic cells were similar sensitive to As2O3 as their wild-type counterpart CCRF-CEM (resistance ratio: 1.88). Drug-resistant U87.MG ΔEGFR glioblastoma cells harboring mutated epidermal growth factor receptor were even more sensitive (collateral sensitive) than wild-type U87.MG cells (…

0301 basic medicineAcute promyelocytic leukemiaBiologyNF-κB03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicinePharmacology (medical)Epidermal growth factor receptorArsenic trioxideTranscription factorOriginal ResearchpharmacogenomicsPharmacologydrug resistancelcsh:RM1-950PromoterAP-1medicine.diseasearsenic trioxidelcsh:Therapeutics. Pharmacology030104 developmental biologychemistryCistromeCell culture030220 oncology & carcinogenesisCancer cellCancer researchbiology.proteinFrontiers in Pharmacology
researchProduct

Retinoic Acid affects Lung Adenocarcinoma growth by inducing differentiation via GATA6 activation and EGFR and Wnt inhibition

2016

AbstractA fundamental task in cancer research aims at the identification of new pharmacological therapies that can affect tumor growth. Differentiation therapy might exploit this function not only for hematological diseases, such as acute promyelocytic leukemia (APML) but also for epithelial tumors, including lung cancer. Here we show that Retinoic Acid (RA) arrests in vitro and in vivo the growth of Tyrosine Kinase Inhibitors (TKI) resistant Non Small Cell Lung Cancer (NSCLC). In particular, we found that RA induces G0/G1 cell cycle arrest in TKI resistant NSCLC cells and activates terminal differentiation programs by modulating the expression of GATA6, a key transcription factor involved …

0301 basic medicineAcute promyelocytic leukemiaScienceEGFRRetinoic acidMice NudeTretinoinBiologyArticle03 medical and health scienceschemistry.chemical_compoundDifferentiation therapySettore BIO/13 - Biologia ApplicataCarcinoma Non-Small-Cell LungCell Line TumorGATA6 Transcription FactormedicineRetinoic acidAnimalsHumansLung cancerProtein Kinase InhibitorsWnt Signaling PathwayTranscription factorCell ProliferationMultidisciplinaryQRWnt signaling pathwayCell Differentiationmedicine.diseaseG1 Phase Cell Cycle CheckpointsXenograft Model Antitumor Assaysrespiratory tract diseasesErbB Receptorslung cancerAnimals; Carcinoma Non-Small-Cell Lung; Cell Differentiation; Cell Line Tumor; Cell Proliferation; Drug Resistance Neoplasm; ErbB Receptors; G1 Phase Cell Cycle Checkpoints; GATA6 Transcription Factor; Humans; Mice Nude; Protein Kinase Inhibitors; Signal Transduction; Tretinoin; Wnt Signaling Pathway; Xenograft Model Antitumor Assays030104 developmental biologychemistryDrug Resistance NeoplasmImmunologyCancer researchMedicineAdenocarcinomaEngineering sciences. TechnologyTyrosine kinaseSignal Transduction
researchProduct

Co-existence of virulence factors and antibiotic resistance in new Klebsiella pneumoniae clones emerging in south of Italy

2018

Abstract Background Endemic presence of Klebsiella pneumoniae resistant to carbapenem in Italy has been due principally to the clonal expansion of CC258 isolates; however, recent studies suggest an ongoing epidemiological change in this geographical area. Methods 50 K. pneumoniae strains, 25 carbapenem-resistant (CR-Kp) and 25 susceptible (CS-Kp), collected from march 2014 to march 2016 at the Laboratory of Bacteriology of the Paolo Giaccone Polyclinic University hospital of Palermo, Italy, were characterized for antibiotic susceptibility and fully sequenced by next generation sequencing (NGS) for the in silico analysis of resistome, virulome, multi-locus sequence typing (MLST) and core sin…

0301 basic medicineAdultKlebsiellaGenotypeKlebsiella pneumoniae030106 microbiologyVirulenceYersiniabactinPolymorphism Single Nucleotidebeta-Lactamaseslcsh:Infectious and parasitic diseasesMicrobiology03 medical and health scienceschemistry.chemical_compoundBacterial ProteinsGenotypeDrug Resistance BacterialHumanslcsh:RC109-216TypingSicilyPhylogenyAgedAged 80 and overbiologyVirulence factorsMiddle Agedbiology.organism_classificationAnti-Bacterial AgentsBacterial Typing TechniquesKlebsiella InfectionsKlebsiella pneumoniae030104 developmental biologyInfectious DiseaseschemistryCarbapenemsCarbapenem-resistant Klebsiella pneumoniaeMultilocus sequence typingAerobactinMultilocus Sequence TypingResearch Article
researchProduct

Effect of ABC transporter expression and mutational status on survival rates of cancer patients

2020

ATP-binding cassette (ABC) transporters mediate multidrug resistance in cancer. In contrast to DNA single nucleotide polymorphisms in normal tissues, the role of mutations in tumors is unknown. Furthermore, the significance of their expression for prediction of chemoresistance and survival prognosis is still under debate. We investigated 18 tumors by RNA-sequencing. The mutation rate varied from 27,507 to 300885. In ABCB1, three hotspots with novel mutations were in transmembrane domains 3, 8, and 9. We also mined the cBioPortal database with 11,814 patients from 23 different tumor entities. We performed Kaplan-Meier survival analyses to investigate the effect of ABC transporter expression …

0301 basic medicineAdultMaleMutation rateNonsense mutationSingle-nucleotide polymorphismATP-binding cassette transporterRM1-950BiologyMultidrug resistanceP-glycoproteinPolymorphism Single Nucleotide03 medical and health sciences0302 clinical medicineNeoplasmsmedicineMissense mutationHumansSurvival analysisAgedCancerPharmacologyAged 80 and overPrognostic factorSequence Analysis RNACancerABCB5General MedicineMiddle AgedSurvival analysismedicine.diseaseMolecular Docking SimulationSurvival Rate030104 developmental biologyABC transporters030220 oncology & carcinogenesisMutationCancer researchATP-Binding Cassette TransportersFemaleTherapeutics. PharmacologyBiomedicine & Pharmacotherapy
researchProduct

Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study.

2018

BACKGROUND Previous reports indicate that patients with chronic spontaneous urticaria (CSU) are undertreated and that physicians show poor adherence to guideline recommendations. Awareness of CSU has improved in recent years, but it remains unclear if this has improved the management of these patients in clinical practice. OBJECTIVE To describe disease burden, quality of life (QoL), and treatment patterns of patients with H1 -antihistamine-refractory CSU in Germany. METHOD A World-wide Antihistamine-Refractory chronic urticaria (CU) patient Evaluation (AWARE) is a global prospective, non-interventional study of CU in the real-world setting, supported by the manufacturer of omalizumab. Patie…

0301 basic medicineAdultMalemedicine.medical_specialtymedicine.medical_treatmentImmunologyMedizinDrug ResistanceOmalizumabOmalizumab03 medical and health sciences0302 clinical medicineQuality of lifeInternal medicinemedicineImmunology and AllergyHumansClinical significanceChronic UrticariaDisease burdenAngioedemabusiness.industryGuidelineDermatology Life Quality IndexMiddle Aged030104 developmental biology030228 respiratory systemHistamine H1 AntagonistsQuality of LifeAntihistamineFemalemedicine.symptombusinessmedicine.drugFollow-Up StudiesClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
researchProduct

Malignant PEComa With Metastatic Disease at Diagnosis and Resistance to Several Chemotherapy Regimens and Targeted Therapy (m-TOR Inhibitor).

2017

Perivascular epithelioid cell tumors (PEComas) are infrequent neoplasms with peculiar myomelanocytic differentiation. The aggressive abdominopelvic variant is rare, with only a small number of published cases. We present an additional case of this unusual variant, which showed an aggressive histologic and clinical behavior with multiple liver metastases and resistance to several therapies. We also discuss the histological and immunohistochemical profiles as well as the differential diagnosis.

0301 basic medicineAdultPathologymedicine.medical_specialtyPerivascular Epithelioid Cell Neoplasmsmedicine.medical_treatmentAntineoplastic AgentsDiseasePathology and Forensic MedicineTargeted therapy03 medical and health sciences0302 clinical medicineMedicineHumansMolecular Targeted TherapyChemotherapybusiness.industryTOR Serine-Threonine Kinasesmedicine.diseasePerivascular Epithelioid Cell Tumors030104 developmental biologyDrug Resistance Neoplasm030220 oncology & carcinogenesisImmunohistochemistrySurgeryFemaleSarcomaAnatomyDifferential diagnosisbusinessInternational journal of surgical pathology
researchProduct

Marine Actinomycetes-Derived Secondary Metabolites Overcome TRAIL-Resistance via the Intrinsic Pathway through Downregulation of Survivin and XIAP

2020

Resistance of cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis represents the major hurdle to the clinical use of TRAIL or its derivatives. The discovery and development of lead compounds able to sensitize tumor cells to TRAIL-induced cell death is thus likely to overcome this limitation. We recently reported that marine actinomycetes&rsquo

0301 basic medicineAquatic OrganismsProgrammed cell deathCell SurvivalSurvivinDown-RegulationSecondary MetabolismX-Linked Inhibitor of Apoptosis ProteinTRAILJurkat cellsArticleTNF-Related Apoptosis-Inducing LigandJurkat Cells03 medical and health sciences0302 clinical medicinemarine actinomycetesDownregulation and upregulationDrug DiscoveryOxazinesSurvivinHumans[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyFADDBenzopyreneslcsh:QH301-705.5ComputingMilieux_MISCELLANEOUSCaspase 8therapybiologyChemistryProdigiosinQuinonesapoptosisGeneral MedicineHCT116 Cells3. Good healthXIAPActinobacteria030104 developmental biologylcsh:Biology (General)Drug Resistance NeoplasmApoptosis030220 oncology & carcinogenesisCancer cellbiology.proteinCancer researchGene DeletionCells
researchProduct

Drug Repurposing of the Anthelmintic Niclosamide to Treat Multidrug-Resistant Leukemia

2017

Multidrug resistance, a major problem that leads to failure of anticancer chemotherapy, requires the development of new drugs. Repurposing of established drugs is a promising approach for overcoming this problem. An example of such drugs is niclosamide, a known anthelmintic that is now known to be cytotoxic and cytostatic against cancer cells. In this study, niclosamide showed varying activity against different cancer cell lines. It revealed better activity against hematological cancer cell lines CCRF-CEM, CEM/ADR5000, and RPMI-8226 compared to the solid tumor cell lines MDA-MB-231, A549, and HT-29. The multidrug resistant CEM/ADR5000 cells were similar sensitive as their sensitive counterp…

0301 basic medicineBiologyPharmacologychemotherapy03 medical and health sciences0302 clinical medicinetranscription factorsmedicineoxidative stressCytotoxic T cellPharmacology (medical)NiclosamideOriginal ResearchpharmacogenomicsPharmacologydrug resistanceNFATmedicine.diseaseGlutathione synthetaseMultiple drug resistanceLeukemia030104 developmental biologyCell culture030220 oncology & carcinogenesisCancer cellmedicine.drugFrontiers in Pharmacology
researchProduct